US FDA panel backs Pfizer’s maternal RSV vaccine for protecting infants
By Raghav Mahobe and Mariam Sunny (Reuters) -Advisers to the U.S. Food and Drug Administration on Thursday backed the safety and effectiveness of Pfizer Inc’s experimental respiratory syncytial virus (RSV) vaccine, boosting its chances of becoming the first available maternal shot to protect babies from the illness. The FDA’s advisory committee voted unanimously that available…
